1DEEDWANIA P C.Hypertension and diabetes: new therapeutice option[J]. Arch Inter Med,2000,160:1 585-1 594.
2American Diabetes Association. Managemant of dyslipidemia in adults with diabetes[J].Diabetes Care,2001,24:S58-S61.
3ODA H,KEANE W F. Recent advances in statins and the kidney[J]. Kidney Int,1999,71(suppl):S2-S5.
4NAKAMARA T,USHIYAMA C,OSADA S,et al. Pioglitazons reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria[J]. Metabolism,2001,50(10):1 193.
5UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes[J]. BMJ,1998,317:703-713.
7PARVING H H,LEHNERT H,BROCHNER-MORTENSEN J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. N Engl Med,2001,345:870-878.
9LEWIS E J,HUNSICKER L G,CLARKE W R,et al.Renoprotective effect of the angiotensin-receptor irbesartan in patients with nephropathy due to type 2 diabetes[J].N Engl J Med,2001,345:851-860.
10BRENNER B M,COOPER M E,ZEEUW D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J]. N Engl J Med,2001,345:861-869.
